JPH06509103A - Preventing and reducing the severity of traumatic injuries - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

[Detailed description of the invention] Preventing and reducing the severity of traumatic injuries field of invention The present invention aims to prevent and treat traumatic injuries by administering silicon compounds. This is related to reducing sensitivity.

Background of the invention Certain diseases, e.g. It has long been known that blood diseases and senile diseases lead to increased susceptibility to traumatic injury. was recognized as being normally nourished and otherwise healthy. Administering certain substances to physically compatible animals or humans to treat trauma The concept of reducing sensitivity is not common.

Silicon in blood, serum, plasma or urine when administered orally or by injection A large number of silicate compounds have been reported for evaluating levels. These include: Sodium silicate, magnesium silicate, amorphous sodium aluminosilicate, and Includes thorium zeolite A. Behnke and Osborg Osborn suggests that sodium zeolite A is particularly effective in this regard. It was shown that Behnke et al., Food, Co5m Sul (Carlisle), Silicon, “Rare Element in Human and Animal Nutrition” (Silicon, “Tr ace Elements in tluman and Animal Nu trition-), 2 volumes, edited by W. Merz, Academic Press. ・See Incorporated, Orlando, 1986. Chapter 7, pp. 373-390. About Teru.

Over the years, many types of zeola have been used in animal feeds for various reasons. Many different experiments have been carried out around the world using these species. These experiments Most of these are in animal nutrition or in food animals or their food This is due to increased production of food products. Animals from which zeolite is supplied These were poultry, cattle, sheep and pigs. Zeolite fed to animals is mainly It was a naturally occurring or naturally found processed zeolite. To some extent in some fields Although some successes were achieved, most results were unfavorable.

CY, Chung, etc., Nongsa Sihom Yaung Bogo saSihom Youngu Pogo), 1978.20 (Livestock), 77- Page 83 contains information on growth, feed efficiency and On the influence of cation exchange capacity and particle size of zeolites on feed material utilization Information regarding is shown. For example, clinoptilolite is used in broiler feed. Supplementation with naturally occurring zeolites results in weight gain.

Chun et al. (1974, 1975, 197 (Rose Aeon, South Korea) uses 1, 5.3, and 4.5% zeolite in layer feed for chickens. They also reported that no significant difference was shown when adding US number 4.393. 082) for example for urea or buoyant animals such as cattle, sheep and goats. Replacement of non-protein nitrogen (NPN) compounds as feed components during feeding The use of zeolites with possible cations is disclosed. natural and synthetic as well as discloses crystalline and amorphous zeolites. using in vitro techniques The zeolites tested included the natural zeolites chabazite and clino Includes petilolite and synthetic zeolites X, YSF, J, MSZ and A. It will be done. Zeolite F was by far the most prominent. Zeolite A is virtually ineffective. It was.

Facts on the use of natural zeolite minerals as feed supplements for poultry, pigs and cattle. Experiments have been underway in Japan since 1965. Increase in body weight per unit of feed consumed and an increase in the general health of the animals has been reported (Minat o), Hideo, Koatsugas, 6: 5 36.1968). Reduction in bad odor was also noted.

U.S. Patent No. 4.847. O85 is a small effective amount of zeolite added to animal feed. or directly into the animal in the form of capsules, tablets, etc. For humans, cattle, sheep, goats, pigs and poultry without adverse effects on animal products. Discloses a method for improving bone quality and/or increasing bone strength in animals comprising: There is.

Zeolites basically consist of a three-dimensional skeleton of Sin and AlO4 tetrahedra. ing. Tetrahedrons are cross-linked by covalent oxygen atoms, so the oxygen atom pairs are The ratio of the sum of aluminum atoms and silicon atoms is equal to 2, i.e. O/(A I+S1)=2. Contains aluminum and is expressed by AI/Na=1 It will be done. The spaces between the tetrahedra are occupied by water molecules before dehydration.

There are many different types of zeolites. Certain zeolites are found naturally and can also be produced synthetically. Other zeolites are made only synthetically Can be built. Zeolite A is not found naturally and is only produced synthetically. be done.

As mentioned above (U.S. Patent No. 4.847.085) Zeolite for Strengthening Bone Discloses nutritional uses of species. The patent describes zeolite useful in the disclosed method. The type and type of zeolite and the method used to produce the zeolite. Disclosed.

An important object of the present invention is to treat metal silicates or are produced by dosing aluminosilicates, especially zeolites. by treating animals with relatively small amounts of silicic acid. The purpose of the present invention is to provide methods for treating, preventing or delaying the effects of traumatic injury.

One object of the present invention is to provide a method for reducing the effects of traumatic injuries in animals, especially humans. Provide animal treatment or feed containing light.

Another object of the invention is to reduce traumatic injuries to both hard and soft tissues in animals. provides a method of treating and/or preventing the effects of of zeolite is added to animal feed.

Still another object of the present invention is to avoid causing adverse effects in animals (on animal tissues). effectively treating, preventing or delaying traumatic injury; Is Rukoto.

Other objects and advantages of the invention will become more fully apparent upon reading the following description and claims. will be understood.

Summary of the invention The present invention provides effective amounts of silicon-containing compounds produced by administering silicon-containing compounds to animals. Traumatic damage to tissues in animals, especially humans, by treating animals with silicic acid The present invention relates to a method of treating, preventing or delaying.

Description of preferred embodiments Conditions known to cause traumatic injury to both hard and soft tissues Treatment of animals with silicic acid can prevent or suppress (delay) the onset of damage. I discovered that it can be extended. Silicic acid is preferably used in animals subjected to traumatic conditions. produced after administering a physiologically acceptable silicon-containing compound, which This results in the production of an effective amount of silicic acid (inside the substance).

The silicon-containing compounds used in the present invention are non-toxic and physiologically acceptable. and is such that when administered to an animal it provides the animal with a source of silicic acid. vinegar That is, the silicon-containing compound may be a purely inorganic or organic silicon compound. can. Regarding the latter, silicate esters are preferred and orthosilicate esters are preferred. ricates, i.e. formula S i (OR)4 [where R is an organic group, e.g. -C, linear or branched alkyl (methyl, ethyl, or n-propyl) is particularly suitable. More than one type of R group may be combined. former metals of compounds such as sodium or potassium, as well as metals of group IIA , such as calcium and magnesium. Examples of such compounds is potassium aluminosilicate, sodium aluminosilicate, calcium Included are aluminosilicates and magnesium aluminosilicates. Zeo Lights, especially zeolite A1, are included in such classes of inorganic silicates. .

Preventing trauma-induced damage by daily administration of small amounts of silicon-containing compounds It has been found that sufficient silicic acid is produced to inhibit or reduce the severity of It was done. When using sodium zeolite A, this may vary depending on the animal. 0.25% to 3.0% of the total feed consumed is effective. Administration can be done by granules, powders, It can be administered in tablets or capsules.

It is well known that traumatic injuries are common in racehorses. traumatic Treatment of animals subjected to conditions shown to cause tissue damage The utility of the method of the present invention in preventing, inhibiting or treating the occurrence of traumatic injury to tissue. To demonstrate efficacy, the following treatments were performed.

In the example below, a group of horses was treated with increasing levels of sodium zeolite A. silica in animals by administering silica and subjecting them to standard training methods. caused it to occur. It should be understood that the examples below are for illustrative purposes only. Ru. They are not intended to limit the invention in any way.

National Research Council (USA) (1989). Concentrate and hay were administered balanced according to Synthon D, C,]. motion The animals are fed twice a day in separate stables and the rest are dry buttocks. I was allowed to exercise freely. ZA is approximately 0, 0.66, 1.33, or 2 of the feed intake. ．． It comprised 0%. Feed is 75% concentrate and 25% Bermuda It consisted of grass hay. The concentrate portion of the feed is 87% granular concentrate (maize). wheat center, soybean flour, alfalfa flour, lignin binder, vinyl Tamin replenisher, ground limestone and trace amounts of gold mineral salts) and 13% From a replenisher of sodium zeolite A granulated with dried alfalfa. It was. In order to maintain a constant volume of replenishment while varying the dosage level of ZA, Alf. 0,6.6.13.3 and 20% sodium zeolite A in alpha particles filled with.

Increase the feeding rate as the animal grows to maintain a nearly constant dose based on body weight. I kept it. Therefore, animals should be given the concentrate portion of their diet (including zero-dose supplements). Approximately 0.2% of body weight (zeolite A-containing) is supplied as a supplement daily as part of It was done. The concentration of zeolite A in the supplement was 6-20% by weight (this is based on body weight represents a zeolite A dosage of 0.12% to 0.4%).

To maintain indistinguishability (blinding), partitions are divided into ASB, D, and C, respectively. Treatments were marked (by He was confined and given treatment irregularly. The male was castrated at 1 year old.

After the June treatment, the animal, which is approximately 1 year old at that time, is placed in a large pigeon with a crib. and optionally refeed with a combination of hay and concentrate under NRC conditions. did. Horses were fed twice a day with 1.82 kg of concentrate feed per fidget. (approximately 1% of body weight over a period of 180 days).

The animals were again given 0.2% of their body weight to zeolite-containing supplements (0 doses) in this concentrate. (including supplements). Adjusted to fluctuating nutritional conditions at this age. To reduce the volume, the ratio of replenisher to remainder of concentrate was increased to 20:80.

At the end of the intermediate June buttock rearing stage, the animal is trained/trained/competitively trained. gram, then adjusted and raced out of the starting gate.

17 weeks of training and training (9 weeks of training and 8 weeks of long leisure) After a combination of distance and sprint conditioning and gate training), animals are trained to compete professionally. I put it in the gram. Animals were allowed to compete every other week. The schedule for the competition week is below. Rules were maintained: Day 1 - Warm-up and 1 mile walk; Day 2 - 1 o'clock at the walking track. Interval Walk = Day 3 - Warm-up, 1/2 mile walk and 150 yard sprint; 4 or and day 5 - walking; day 6 - racing; day 7 - stable rest. The competition is based on the distance as shown below. Conducted in increments: Race 1 - 3,300 yards, Race 4 - 6.350 yards; Competition 7-9.400 yards. In non-competitive weeks, the weekly schedule is 1 and and Day 3 - Warm-up and 1.5 mile walk; Day 2.4.6 and 7 - Walking: Day 5 - Warm-up, 1/2 mile walk and 200 yard sprint 0.30 concentrate Supplied at a ratio of hay to hay. As during the previous stage, the concentrate portion of the feed is It consisted of a 20=80 ratio of Olite A-containing replenisher to granular concentrate.

Treatment regimen was maintained throughout the study. Trainers, jockeys, veterinarians, and handling/diagnosis The patient and other persons subjected to the treatment were blinded to the composition of the treatment. .

Over a period of three months starting on February 7th and ending on May 29th, six groups of animals will be The first competition began according to their age. Animals coordinating them and running as fast as they can /Assessed for injuries sustained as a result of trauma caused by locomotion. .

Animals were evaluated on May 28th. it as a result of training or competition at some point They are unable to run at a certain speed due to trauma caused by running/running at full speed. They were defined as being damaged. At this point, the first horse has eight races. and the last registered horse had completed three races. Soft and Both hard tissue damage and hard tissue damage were measured.

Percentage of injuries within each group evaluated as distance and number of walks leading to injury It was done. One animal was injured in an accident at the walking track. it is not included in the analysis It was. The other animals were injured before entering the walking/sprinting phase of the study, but were not able to receive regular training. He had recovered enough to continue training/competitive exercise. This animal was included in the analysis . within a competitive schedule by using distance run or number of steps taken before the initial injury. Regardless of progression, the average distance covered before the first injury in the comparison group is as follows: Met.

Dosage (%ZA) Percentage Injury Distance vs. Initial Wound - Strides/Yards 0,0 62 8537/41151 6, 66 36 13665/6500513, 3 33 15380/713 5820, 0　27　14901/68534 Injuries were treated as follows and group 1 Sorted by number of animals per unit (N): Treatment (%ZA)/(N) Damage 0, 0/(13) Fractured seed front swollen hind legs bone sprain Sesamoiditis/possible fractures I can't move swollen hind legs Intermittent limp in left front leg 6, 66/(14) Canal osteomyelitis Rear end recline canal osteomyelitis canal osteomyelitis canal osteomyelitis 13, 3/(9) Knee fragment/fractured sesamoid bone/extremely thin fracture of arthritic wrist bone flexed legs bent key Data were collected on horses injured during conditioning or competition. Evaluate similar conditions For this purpose, only horses injured under the conditioning loads of galloping or sprinting were analyzed. horse exercising If you are disqualified due to an accident unrelated to the event or before entering the training/competition stage. horses were excluded from the analysis. Exclusions are evenly distributed across treatments and was not related to treatment due to the following causes: 1) Bikko's right front leg. (Occurred during training.) One horse - Treatment D02) Osteogenic related physitis (genetic cause - same stallion).

One animal per device B and C0 3) Osteochondrosis. (It was there on arrival.) Treatment D4) Fracture - fragmented knee, sesamoid bone . (This happened during training.) One animal at a time, equipment A and Do. Apparently, the treatment reduced both hard and soft tissue injuries in a dose-related manner. brought about.

Example 2 Blood is taken from the horse at intervals during the test and analyzed for its silicon content. did. To measure the level of silicon in plasma, Gitelman ) and Alderman (^], derman) were used. Gitelman, H, J and Alderman, F, R, 1991, [Electrothermal Atomic Absorption Determination of silicon in biological samples using optical radiation (Detern+1natio n, of silicon in biological samples us ing electrothermal atomic absor■ Spectrometry (J, Analytical Atomic Spe 5:687° Zeolite A treatment dose-dependently It was found to increase silicon levels. The sample was taken just before feeding (T=O) , and at 1.3.6 and 9 hours after feeding. 0.3.6 and Average plasma silicon level using the average of evenly spaced samples over 9 hours was calculated.

Plasma silicon levels after 84 days of treatment were as follows: Plasma Si (mg/d 1) Dose (%ZA) Dansei Do J Tu Review 6M 91&’l Wangfu 0.0 3.15 3.08 3.54 3.40 3.296.66 5,26 5,62 7 ．． 57 6.17 6.161.3.3 6.17 7.35 10.3 7. 95 7.9420 5.88 7,78 9.73 9.90 8.32 Implemented As can be seen, this treatment lowers the average plasma level of silicon in treated horses. This resulted in a dose-related increase. Increased systemic silicon levels are shown in Example 1. It has been associated with decreased susceptibility to traumatic injury.

It will be appreciated by those skilled in the art that the utility of the invention is general. Probably. This is due to common elements of traumatic injuries, regardless of cause.

Therefore, the utility of the present invention is not limited to athletic injuries. Other uses For example, the International V4 Survey Report for Poultry, Cattle, Horses, Pig and Humans international search report international search report

Claims (14)

[Claims] 1. an effective amount of silicic acid produced by the animal from a silicon compound administered to the animal; a hard or soft tissue body in an animal comprising treating said animal; How to prevent or delay traumatic injuries. 2. 2. The method of claim 1, wherein the tissue is a hard tissue. 3. 2. The method of claim 1, wherein the tissue is soft tissue. 4. The method according to claim 1, wherein the silicon compound is an organosilicon compound. . 5. The method according to claim 1, wherein the silicon compound is an inorganic silicon compound. . 6. 6. The method of claim 5, wherein the silicon compound is a zeolite. 7. 6. The method of claim 5, wherein the zeolite is Zeolite A. 8. an effective amount of silicic acid produced by an animal from zeolite A administered to the animal; a hard or soft tissue body in an animal comprising treating said animal; How to prevent or delay traumatic injuries. 9. 9. The method of claim 8, wherein the animal treated is a human. 10. Claim 8, wherein the animal to be treated is a horse, cow, dog, cat, pig or poultry. The method described in section. 11. 11. The method of claim 10, wherein the animal is a horse. 12. Administered to humans at about 0.25 to about 3.00% by weight of a human's daily food intake. treating the human with an effective amount of silicic acid produced by the human from zeolite A prevention or prevention of physical damage to hard or soft tissues in humans, is a delay method. 13. Claim 12, wherein the dose is 0.12-0.4% of body weight. Method. 14. The claim is that the zeolite A is administered in tablet, granule, powder or capsule form. The method according to item 12.